(A) Experiment schematic and song system. Carbachol (Carb) was microdialyzed into HVC. HVC receives a cholinergic projection from a homolog of the nucleus basalis (ACh, red). The avian song control system consists of a direct motor pathway that includes the cortical nuclei HVC (used as a proper name) and RA (the robust nucleus of the arcopallium), which projects to the brainstem premotor regions that control vocal musculature; and an Anterior Forebrain Pathway (AFP) that includes the basal ganglia homologue Area X, the thalamic nucleus DLM (the dorsolateral nucleus of the medial thalamus), and the cortical nucleus LMAN (the lateral magnocellular nucleus of the anterior nidopallium), which projects back to the motor pathway at the level of RA. (B) Example song bouts before and after carbachol. (C) Change in pitch produced by carbachol for one example syllable (one experiment). Left, time course of raw pitch values. Red points indicate data used for analysis of carbachol effects (60–180 min. following onset of dialysis). Top right, rendition-averaged spectrograms. Lower right, pitch distributions during baseline (black) and Carb (red) conditions. (D) Normalized (drug/baseline) pitch (mean ± s.e.m. increase in pitch for Carb: 1.2 ± 0.21%, n = 20 experiments; Saline: 0.34 ± 0.11%, n = 17 experiments; Carb+Atrp: 0.31 ± 0.16%, n = 10 experiments; Carb+MEC+MLA: 1.5 ± 0.24%, n = 10 experiments; Carb vs. Saline, p=0.00088, two-tailed signed-rank test, n = 22 syllables, eight birds; Carb+Atrp vs. Carb+MEC+MLA, p=0.00024, two-tailed signed-rank test, n = 14 syllables, five birds). (E) Normalized (drug/baseline) pitch c.v. (mean ± s.e.m. reduction in pitch c.v. for Carb: 13 ± 1.6%, n = 20 experiments; Saline: 1.4 ± 2.7%, n = 17 experiments; Carb+Atrp: 4.0 ± 1.7%, n = 10 experiments; Carb+MEC+MLA: 14 ± 2.9%, n = 10 experiments; Carb vs. Saline, p=0.0014, two-tailed signed-rank test, n = 22 syllables, eight birds; Carb+Atrp vs. Carb+MEC+MLA, p=0.0023, two-tailed signed-rank test, n = 14 syllables, five birds). (F) Rendition-averaged spectrograms of one example syllable sequence before and after carbachol (one experiment). (G) Normalized (drug/baseline) syllable sequence duration (mean ± s.e.m. reduction in sequence duration for Carb: 2.8 ± 0.43%, n = 20 experiments; Saline: 0.26 ± 0.20%, n = 15 experiments; Carb+Atrp: 0.25 ± 0.39%, n = 9 experiments; Carb+MEC+MLA: 2.2 ± 0.51%, n = 10 experiments; Carb vs. Saline, p=0.00024, two-tailed signed-rank test, n = 13 syllable sequences, eight birds; Carb+Atrp vs. Carb+MEC+MLA, p=0.078, two-tailed signed-rank test, n = 8 syllable sequences, five birds). (H) Amplitude envelopes (mean ± s.e.m.) for one example syllable before and after carbachol (one experiment). Amplitude envelopes were normalized to the maximum value in the carbachol condition. (I) Normalized (drug/baseline) amplitude (mean ± s.e.m. increase in amplitude for Carb: 8.3 ± 2.5%, n = 18 experiments; Saline: 0.99 ± 1.6%, n = 17 experiments; Carb+Atrp: −3.2 ± 2.4%, n = 10 experiments; Carb+MEC+MLA: 6.1 ± 3.1%, n = 9 experiments; Carb vs. Saline, p=0.012, two-tailed signed-rank test, n = 30 syllables, eight birds; Carb+Atrp vs. Carb+MEC+MLA, p=0.0033, two-tailed signed-rank test, n = 18 syllables, five birds). ***p<0.001, **p<0.01, *p<0.05. For panels D, E, G, and I, each point represents one syllable or syllable sequence averaged over experiments; Atrp = the muscarinic antagonist atropine; MEC and MLA = the nicotinic antagonists mecamylamine and methyllycaconitine.